A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors.

A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors.

scientific article

Author/s

Work details

Publication date: August 1, 2006

Language: English

Country of origin: Unknown

Copyright status

Copyright status information is not available for this work. The copyright status depends on the jurisdiction, the author's date of death and the date the work was created or published.

To learn more about copyright terms in different countries, visit the countries and terms page.